The Lancet Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• Reduced ability to engage in social and physical activity and mental health of older adults during the COVID-19 pandemic: longitudinal analysis from the Canadian Longitudinal Study on Aging 2021
• Understanding the impact of a new public health approach to end-of-life care: a qualitative study of a community led intervention 2017
• Coordination of health-service provision in humanitarian crises: a systematic review of suggested models 2017
• Establishing disability weights for congenital paediatric surgical disease: a cross-sectional, multi-modal study 2013
• Global, regional, and national progress towards the 2030 global nutrition targets and forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2021..  404:2543-2583. 2025
• Integrating environmental outcomes in randomised clinical trials: a call to action..  S0140-6736(24)02666-7. 2024
• Burden of disease scenarios by state in the USA, 2022-50: a forecasting analysis for the Global Burden of Disease Study 2021..  404:2341-2370. 2024
• National-level and state-level prevalence of overweight and obesity among children, adolescents, and adults in the USA, 1990-2021, and forecasts up to 2050..  404:2278-2298. 2024
• Equitable access to pandemic products demands stronger public governance..  404:2030-2032. 2024
• Global, regional, and national stillbirths at 20 weeks' gestation or longer in 204 countries and territories, 1990-2021: findings from the Global Burden of Disease Study 2021..  404:1955-1988. 2024
• Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial..  404:S0140-6736(24)02197-4. 2024
• Global burden of bacterial antimicrobial resistance 1990-2021: a systematic analysis with forecasts to 2050..  404:1199-1226. 2024
• Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis..  404:764-772. 2024
• Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials..  404:753-763. 2024
• Activity limitations, use of assistive devices, and mortality and clinical events in 25 high-income, middle-income, and low-income countries: an analysis of the PURE study.  404:554-569. 2024
• Counting the dead in Gaza: difficult but essential.  404:237-238. 2024
• Long-term colchicine for the prevention of vascular recurrent events in non-cardioembolic stroke (CONVINCE): a randomised controlled trial.  404:125-133. 2024
• Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial.  403:2405-2415. 2024
• Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.  403:2734-2746. 2024
• Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial.  403:2416-2425. 2024
• Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.  403:2597-2605. 2024
• Rates and causes of death after release from incarceration among 1 471 526 people in eight high-income and middle-income countries: an individual participant data meta-analysis..  403:1779-1788. 2024
• Burden of disease scenarios for 204 countries and territories, 2022–2050: a forecasting analysis for the Global Burden of Disease Study 2021.  403:2204-2256. 2024
• Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.  403:1989-2056. 2024
• Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021.  403:2162-2203. 2024
• Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021.  403:2100-2132. 2024
• Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021.  403:2057-2099. 2024
• Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021.  403:2133-2161. 2024
• Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.  403:e21-e31. 2024
• Prioritising actions to address stagnating maternal mortality rates globally.  403:417-419. 2024
• Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.  402:2295-2306. 2023
• Effect of colchicine on perioperative atrial fibrillation and myocardial injury after non-cardiac surgery in patients undergoing major thoracic surgery (COP-AF): an international randomised trial.  402:1627-1635. 2023
• Effective and safe regional node irradiation in early breast cancer.  402:1943-1945. 2023
• Inhibition of neonatal Fc receptor as a treatment for immune thrombocytopenia.  402:1599-1601. 2023
• Malnutrition in older adults: a wider view.  402:1976-1976. 2023
• The Lancet Commission on peaceful societies through health equity and gender equality.  402:1661-1722. 2023
• Anticoagulation in patients with cerebral amyloid angiopathy.  402:1418-1419. 2023
• Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021.  402:203-234. 2023
• Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial.  402:118-128. 2023
• Cognitive functional therapy for chronic disabling low back pain..  401:1828-1829. 2023
• Latent bipolar disorder.  401:2109-2109. 2023
• Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.  401:1853-1865. 2023
• Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.  401:269-280. 2023
• Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.  400:2221-2248. 2022
• Revisiting RECORD4.  400:2047-2048. 2022
• WHO Living Guidelines on antivirals for COVID-19 are evidence-based.  400:2196-2198. 2022
• Personalised cooler dialysate for patients receiving maintenance haemodialysis (MyTEMP): a pragmatic, cluster-randomised trial.  400:1693-1703. 2022
• The polypill: from concept and evidence to implementation.  400:1661-1663. 2022
• Aqueous skin antisepsis before surgical fixation of open fractures (Aqueous-PREP): a multiple-period, cluster-randomised, crossover trial.  400:1334-1344. 2022
• Suture choice for cervical cerclage.  400:1385-1387. 2022
• Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials.  400:832-845. 2022
• Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.  400:997-1007. 2022
• Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.  7:796-829. 2022
• Metabolic, behavioural, and psychosocial risk factors and cardiovascular disease in women compared with men in 21 high-income, middle-income, and low-income countries: an analysis of the PURE study.  400:811-821. 2022
• Radiation doses and fractionation schedules in non-low-risk ductal carcinoma in situ in the breast (BIG 3–07/TROG 07.01): a randomised, factorial, multicentre, open-label, phase 3 study.  400:431-440. 2022
• The global burden of cancer attributable to risk factors, 2010–19: a systematic analysis for the Global Burden of Disease Study 2019.  400:563-591. 2022
• WHO must live up to its values and include data on Palestinians.  400:427-427. 2022
• Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.  400:161-169. 2022
• Viral hepatitis elimination: a challenge, but within reach.  400:251-251. 2022
• Coeliac disease.  399:2413-2426. 2022
• Measuring the availability of human resources for health and its relationship to universal health coverage for 204 countries and territories from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019.  399:2129-2154. 2022
• Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial.  399:2200-2211. 2022
• Aggressive intraoperative warming versus routine thermal management during non-cardiac surgery (PROTECT): a multicentre, parallel group, superiority trial.  399:1799-1808. 2022
• Challenging dogma about perioperative warming during non-cardiac surgery.  399:1757-1759. 2022
• The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.  399:1886-1901. 2022
• A call for an immediate ceasefire and peaceful end to the Russian aggression against Ukraine.  399:1284-1287. 2022
• Disease-modifying anti-asthmatic drugs.  399:1664-1668. 2022
• Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial.  399:1391-1400. 2022
• Evaluating COVID-19 vaccines in the real world.  399:1205-1206. 2022
• Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial.  399:945-955. 2022
• Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability.  399:487-494. 2022
• Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.  399:259-269. 2022
• Racialised people in clinical guideline panels.  399:139-140. 2022
• The Lancet Commission on the future of care and clinical research in autism.  399:271-334. 2022
• COV-BOOST: evidence to support rapid booster deployment Comment.  398:2209-2211. 2021
• PCI versus CABG for left main coronary artery disease: is the jury still out?.  398:2208-2209. 2021
• Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.  398:1803-1810. 2021
• Global, regional, and national mortality among young people aged 10–24 years, 1950–2019: a systematic analysis for the Global Burden of Disease Study 2019.  398:1593-1618. 2021
• Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050.  398:1317-1343. 2021
• Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.  398:1053-1064. 2021
• Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis.  398:1133-1146. 2021
• The use of inhaled corticosteroids in early-stage COVID-19.  398:818-819. 2021
• Measuring routine childhood vaccination coverage in 204 countries and territories, 1980–2019: a systematic analysis for the Global Burden of Disease Study 2020, Release 1.  398:503-521. 2021
• Revisiting the evidence for physical distancing, face masks, and eye protection – Authors' reply.  398:663-664. 2021
• WHO COVID-19 therapeutic guidelines.  398:117-118. 2021
• Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019.  397:2337-2360. 2021
• Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.  397:1625-1636. 2021
• Priorities for COVID-19 research response and preparedness in low-resource settings.  397:1866-1868. 2021
• Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies (vol 388, pg 465, 2016).  397:1350-1350. 2021
• Hearing loss prevalence and years lived with disability, 1990–2019: findings from the Global Burden of Disease Study 2019.  397:996-1009. 2021
• How low can we go in community-acquired pneumonia therapy?.  397:1160-1161. 2021
• Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.  397:475-486. 2021
• COVID-19 vaccines for Palestinians.  397:579-579. 2021
• Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.  397:499-509. 2021
• Public policy and health in the Trump era.  397:705-753. 2021
• Recognising HIV infection in systems of care for stroke – Authors' reply.  397:794-795. 2021
• Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme.  397:581-591. 2021
• Causal ordering among risk factors in the PURE study – Authors' reply.  397:279-279. 2021
• Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries.  397:387-397. 2021
• Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.  396:1895-1904. 2020
• Direct oral anticoagulants: evidence and unresolved issues.  396:1767-1776. 2020
• Emergency use authorisation for COVID-19 vaccines: lessons from Ebola.  396:1707-1709. 2020
• Surgery during the COVID-19 pandemic.  396:e74-e74. 2020
• Accelerated surgery for hip fractures—the HIP ATTACK results discussed – Authors' reply.  396:1332-1332. 2020
• Five insights from the Global Burden of Disease Study 2019.  396:1135-1159. 2020
• Global age-sex-specific fertility, mortality, healthy life expectancy (HALE), and population estimates in 204 countries and territories, 1950–2019: a comprehensive demographic analysis for the Global Burden of Disease Study 2019.  396:1160-1203. 2020
• Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.  396:1204-1222. 2020
• Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.  396:1223-1249. 2020
• Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.  396:1250-1284. 2020
• Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis.  396:968-976. 2020
• Stroke systems of care in low-income and middle-income countries: challenges and opportunities.  396:1443-1451. 2020
• Health sector spending and spending on HIV/AIDS, tuberculosis, and malaria, and development assistance for health: progress towards Sustainable Development Goal 3.  396:693-724. 2020
• After COVID-19, a future for the world's children?.  396:298-300. 2020
• Cardiovascular risk in hypertension: open questions about HOPE 4 – Authors' reply.  396:310-311. 2020
• Solidarity in the wake of COVID-19: reimagining the International Health Regulations.  396:82-83. 2020
• Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.  396:97-109. 2020
• Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017 (vol 395, pg 1779, 2020).  395:1762-1762. 2020
• Department of Error.  395:1762-1762. 2020
• Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial.  395:1927-1936. 2020
• Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000–17: analysis for the Global Burden of Disease Study 2017.  395:1779-1801. 2020
• Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis.  395:1973-1987. 2020
• What does it mean to be made vulnerable in the era of COVID-19? (vol 395, pg 1481, 2020).  395:1486-1486. 2020
• What does it mean to be made vulnerable in the era of COVID-19?.  395:1481-1482. 2020
• Efficacy and safety of nerinetide for the treatment of acute ischaemic stroke (ESCAPE-NA1): a multicentre, double-blind, randomised controlled trial.  395:878-887. 2020
• Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.  395:795-808. 2020
• Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study.  395:785-794. 2020
• A future for the world's children? A WHO–UNICEF–Lancet Commission.  395:605-658. 2020
• Do not violate the International Health Regulations during the COVID-19 outbreak.  395:664-666. 2020
• Dulaglutide slows kidney disease in type 2 diabetes − Author's reply.  395:559-560. 2020
• Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.  395:709-733. 2020
• Perception of severity of adverse events in oral immunotherapy – Authors' reply.  395:415-416. 2020
• Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial.  395:698-708. 2020
• External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial.  394:2165-2172. 2019
• A roadmap for sustainably governing the global antimicrobial commons.  394:1788-1789. 2019
• A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial.  394:1231-1242. 2019
• Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study.  394:1344-1351. 2019
• Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study.  394:1022-1029. 2019
• Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial.  394:1181-1190. 2019
• Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial.  394:1169-1180. 2019
• The evolution of fractionated prostate cancer radiotherapy.  394:361-362. 2019
• The importance of randomised vs non-randomised trials – Authors' reply.  394:635-635. 2019
• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.  394:121-130. 2019
• Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.  394:131-138. 2019
• Department of Error.  393:e44-e44. 2019
• Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety.  393:2222-2232. 2019
• Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.  393:1937-1947. 2019
• Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.  393:1819-1830. 2019
• Urinary sodium excretion measures and health outcomes-Authors' reply (vol 393, pg 1295, 2019).  393:1596-1596. 2019
• Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials.  393:1440-1452. 2019
• Urinary sodium excretion measures and health outcomes – Authors' reply.  393:1295-1296. 2019
• Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.  393:407-415. 2019
• Gender bias in academia.  393:741-743. 2019
• Time for gender-transformative change in the health workforce.  393:e25-e26. 2019
• Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial.  393:265-274. 2019
• Real-world studies no substitute for RCTs in establishing efficacy.  393:210-211. 2019
• The MANAGE trial – Authors' reply.  393:228-228. 2019
• Canada's global health role – Authors' reply.  392:2350-2351. 2018
• Discrepancies in guidelines for acute respiratory distress syndrome.  392:2550-2551. 2018
• Oxygenation targets in acutely ill patients: still a matter of debate – Authors' reply.  392:2437-2438. 2018
• GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in;195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017 (vol 392, pg 1736, 2018).  392:2170-2170. 2018
• Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study.  392:2288-2297. 2018
• Department of Error.  392:2170-2170. 2018
• Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial.  392:2269-2279. 2018
• Global, regional, and national age-sex-specific mortality and life expectancy, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017.  392:1684-1735. 2018
• Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017.  392:1736-1788. 2018
• Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.  392:1923-1994. 2018
• Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.  392:1859-1922. 2018
• Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017.  392:1789-1858. 2018
• Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017.  392:2091-2138. 2018
• Patient outcomes after screw fixation of hip fractures – Authors' reply.  392:2265-2266. 2018
• Population and fertility by age and sex for 195 countries and territories, 1950–2017: a systematic analysis for the Global Burden of Disease Study 2017.  392:1995-2051. 2018
• Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.  392:1519-1529. 2018
• Saudi visa trainees called home from Canada in diplomatic dispute.  392:815-816. 2018
• Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.  392:821-834. 2018
• Esomeprazole and aspirin in Barrett's oesophagus (AspECT): a randomised factorial trial.  392:400-408. 2018
• Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study.  392:496-506. 2018
• Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial (vol 391, pg 2325, 2018).  392:30-30. 2018
• Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial.  391:2325-2334. 2018
• Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study.  391:2213-2224. 2018
• Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016.  391:2236-2271. 2018
• Global governance of antimicrobial resistance.  391:1976-1978. 2018
• Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study.  391:2019-2027. 2018
• The gendered system of academic publishing.  391:1754-1756. 2018
• Associations of fats and carbohydrates with cardiovascular disease and mortality—PURE and simple? – Authors' reply.  391:1681-1682. 2018
• Canada's global health role: supporting equity and global citizenship as a middle power.  391:1736-1748. 2018
• Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis.  391:1693-1705. 2018
• Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis.  391:1197-1204. 2018
• Cardiovascular, respiratory, and related disorders: key messages from Disease Control Priorities, 3rd edition.  391:1224-1236. 2018
• Evidence-based guidelines for supportive care of patients with Ebola virus disease.  391:700-708. 2018
• Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial (vol 391, pg 205, 2017).  391:204-204. 2018
• Hyperparathyroidism.  391:168-178. 2018
• Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial.  391:205-218. 2018
• Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.  391:219-229. 2018
• Health workers and the weaponisation of health care in Syria: a preliminary inquiry for The Lancet –American University of Beirut Commission on Syria.  390:2516-2526. 2017
• The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study.  390:2643-2654. 2017
• On evidence-based medicine Reply.  390:2245-2246. 2017
• Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study.  390:2050-2062. 2017
• Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial.  390:2347-2359. 2017
• Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study.  390:2037-2049. 2017
• Indigenous health data and the path to healing.  390:2022-2023. 2017
• On evidence-based medicine – Authors' reply.  390:2245-2246. 2017
• Department of Error.  390:e38-e38. 2017
• Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.  390:1949-1961. 2017
• Department of Error.  390:e23-e23. 2017
• Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016.  390:1151-1210. 2017
• Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.  390:1345-1422. 2017
• Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.  390:1260-1344. 2017
• Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016.  390:1211-1259. 2017
• Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016.  390:1084-1150. 2017
• Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016.  390:1423-1459. 2017
• Optimal timing of an invasive strategy in patients with non-ST-elevation acute coronary syndrome: a meta-analysis of randomised trials.  390:737-746. 2017
• Procalcitonin-guided decision making for duration of antibiotic therapy in neonates with suspected early-onset sepsis: a multicentre, randomised controlled trial (NeoPIns).  390:871-881. 2017
• Eliminating acute rheumatic fever and rheumatic heart disease.  390:212-213. 2017
• Evidence for underuse of effective medical services around the world.  390:169-177. 2017
• Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the Global Burden of Disease Study 2015.  390:231-266. 2017
• Levers for addressing medical underuse and overuse: achieving high-value health care.  390:191-202. 2017
• Progress in evidence-based medicine: a quarter century on.  390:415-423. 2017
• Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.  389:2226-2237. 2017
• Fracture fixation in the operative management of hip fractures (FAITH): an international, multicentre, randomised controlled trial.  389:1519-1527. 2017
• On the economics of managing blood pressure.  389:1294-1295. 2017
• Palliative care in humanitarian crises: always something to offer.  389:1498-1499. 2017
• Risk of mortality and stroke after atrial fibrillation – Authors' reply.  389:907-907. 2017
• Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study (vol 388, pg 1161, 2016).  389:602-602. 2017
• Understanding the impact of a new public health approach to end-of-life care: a qualitative study of a community led intervention.  389:S88-S88. 2017
• 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.  389:1399-1409. 2017
• Nurturing care: promoting early childhood development.  389:91-102. 2017
• Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study.  389:157-166. 2017
• The INTERSTROKE study on risk factors for stroke – Authors' reply.  389:36-36. 2017
• Interpretation of the evidence for the efficacy and safety of statin therapy.  388:2532-2561. 2016
• Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.  388:2128-2141. 2016
• Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015..  388:1725-1774. 2016
• Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.  388:2128-2141. 2016
• Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial.  388:1995-2003. 2016
• Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.  388:1659-1724. 2016
• Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.  388:1603-1658. 2016
• Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.  388:1545-1602. 2016
• Global, regional, and national levels of maternal mortality, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.  388:1775-1812. 2016
• Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015.  388:1725-1774. 2016
• Hypertrophic scarring: the greatest unmet challenge after burn injury.  388:1427-1436. 2016
• Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015.  388:1813-1850. 2016
• Sodium and cardiovascular disease – Authors' reply.  388:2113-2114. 2016
• Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study.  388:1161-1169. 2016
• Why do people not take life-saving medications? The case of statins.  388:943-945. 2016
• Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.  388:761-775. 2016
• Unresolved issues in Canada's law on physician-assisted dying.  388:545-547. 2016
• Associations of urinary sodium excretion with cardiovascular events in individuals with and without hypertension: a pooled analysis of data from four studies.  388:465-475. 2016
• UN High-Level Meeting on antimicrobials—what do we need?.  388:218-220. 2016
• The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study.  387:2302-2311. 2016
• Breastfeeding in the 21st century.  387:2088-2089. 2016
• Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial.  387:1066-1074. 2016
• Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data..  387:61-69. 2016
• Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data.  387:61-69. 2016
• International cooperation to improve access to and sustain effectiveness of antimicrobials.  387:296-307. 2016
• Late preterm rupture of membranes: it pays to wait.  387:406-408. 2016
• Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial.  387:127-135. 2016
• Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.  386:2287-2323. 2015
• Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study.  386:1945-1954. 2015
• Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition.  386:2145-2191. 2015
• Radiation exposure in relation to the arterial access site used for diagnostic coronary angiography and percutaneous coronary intervention: a systematic review and meta-analysis.  386:2192-2203. 2015
• Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials.  386:1341-1352. 2015
• Controversies in faith and health care.  386:1776-1785. 2015
• Understanding the roles of faith-based health-care providers in Africa: review of the evidence with a focus on magnitude, reach, cost, and satisfaction.  386:1765-1775. 2015
• Is crowdfunding a viable source of clinical trial research funding? (vol 386, pg 338, 2015).  386:1136-1136. 2015
• Corticosteroid therapy for pneumonia – Author's reply.  386:956-956. 2015
• Department of Error.  386:1136-1136. 2015
• Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial.  386:1243-1253. 2015
• Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.  386:541-551. 2015
• Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.  386:743-800. 2015
• Is crowdfunding a viable source of clinical trial research funding?.  386:338-338. 2015
• Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study.  386:266-273. 2015
• The World Heart Federation's vision for worldwide cardiovascular disease prevention.  386:399-402. 2015
• Coronary intervention: radial artery access comes of age.  385:2437-2439. 2015
• Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.  385:2067-2076. 2015
• Living kidney donation: outcomes, ethics, and uncertainty.  385:2003-2013. 2015
• Worldwide access to treatment for end-stage kidney disease: a systematic review.  385:1975-1982. 2015
• Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.  385:1511-1518. 2015
• Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials.  385:1397-1405. 2015
• Musculoskeletal trauma and all-cause mortality in India: a multicentre prospective cohort study.  385:S30-S30. 2015
• Effects of blood pressure lowering on cardiovascular risk according to baseline body-mass index: a meta-analysis of randomised trials.  385:867-874. 2015
• Effects of intensive glycaemic control on ischaemic heart disease – Authors' reply.  385:1180-1181. 2015
• Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE).  385:785-791. 2015
• The burden of disease in older people and implications for health policy and practice.  385:549-562. 2015
• Trading health for oil? Uganda should not export its health workers.  385:e13-e13. 2015
• Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.  385:117-171. 2015
• Iran: the health cost of a political order..  384:1926-1927. 2014
• Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial.  384:1673-1683. 2014
• Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial.  384:1936-1941. 2014
• Ebola control: effect of asymptomatic infection and acquired immunity.  384:1499-1500. 2014
• The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial.  384:1446-1454. 2014
• Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.  384:1005-1070. 2014
• Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.  384:980-1004. 2014
• Global, regional, and national levels of neonatal, infant, and under-5 mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.  384:957-979. 2014
• Blood pressure-lowering treatment based on cardiovascular risk: a meta-analysis of individual patient data.  384:591-598. 2014
• International comparisons of acute myocardial infarction.  384:304-304. 2014
• Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials.  383:2127-2135. 2014
• Radiotherapy for breast cancer, the TARGIT-A trial.  383:1716-1717. 2014
• Burns in children: standard and new treatments.  383:1168-1178. 2014
• Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.  383:955-962. 2014
• Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial.  383:880-888. 2014
• Premature mortality in patients with epilepsy.  383:511-511. 2014
• Global and regional burden of stroke during 1990–2010: findings from the Global Burden of Disease Study 2010.  383:245-255. 2014
• Cangrelor: a new CHAMPION for percutaneous coronary intervention.  382:1960-1962. 2013
• Experiencing regrets in clinical practice.  382:1553-1554. 2013
• Global health governance after 2015.  382:1018-1018. 2013
• Prevalence of abuse and intimate partner violence surgical evaluation (PRAISE) in orthopaedic fracture clinics: a multinational prevalence study.  382:866-876. 2013
• Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial.  382:507-515. 2013
• Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.  382:780-789. 2013
• Extra-couple HIV transmission in sub-Saharan Africa: a mathematical modelling study of survey data.  381:1561-1569. 2013
• Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals.  381:1029-1036. 2013
• Ongoing bleeding in acute intracerebral haemorrhage.  381:152-152. 2013
• Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010.  380:2197-2223. 2012
• Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.  380:2095-2128. 2012
• Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010.  380:2163-2196. 2012
• Pulse oximetry screening for critical congenital heart defects.  380:1305-1306. 2012
• Advances and future directions for management of trauma patients with musculoskeletal injuries.  380:1109-1119. 2012
• Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study.  380:572-580. 2012
• The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials.  380:581-590. 2012
• WHO's undermining tobacco control.  380:727-728. 2012
• Is regression to normoglycaemia clinically important?.  379:2216-2218. 2012
• The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.  379:2352-2363. 2012
• Does aspirin really reduce the risk of colon cancer?.  379:1586-1587. 2012
• Surfactant treatment for spontaneously breathing preterm infants.  379:1589-1589. 2012
• A flawed Bill with a hidden purpose.  379:999-999. 2012
• AIDA STEMI: no benefit for intracoronary abciximab.  379:875-877. 2012
• Burn size and survival probability in paediatric patients in modern burn care: a prospective observational cohort study.  379:1013-1021. 2012
• Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials.  379:432-444. 2012
• How the Health and Social Care Bill 2011 would end entitlement to comprehensive health care in England.  379:387-389. 2012
• Erratum: Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study (The Lancet (2012) DOI:10.1016/S0140-6736(12) 60312-2).  380:564. 2012
• Idrabiotaparinux treatment for venous thromboembolism.  379:96-98. 2012
• A framework convention on obesity control?.  378:2068-2068. 2011
• No evidence that patient choice in the NHS saves lives.  378:2057-2060. 2011
• Ending medical complicity in state-sponsored torture.  378:1535-1537. 2011
• Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.  378:1231-1243. 2011
• Aerosol drug delivery: developments in device design and clinical use – Authors' reply.  378:982-982. 2011
• Continued neglect of ageing of HIV epidemic at UN meeting.  378:768-768. 2011
• Radial versus femoral access in acute coronary syndromes – Authors' reply.  378:661-662. 2011
• Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.  378:771-784. 2011
• Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. (vol 377, pg 1409, 2011).  378:30-30. 2011
• Body-mass index, abdominal adiposity, and cardiovascular risk.  378:226-227. 2011
• Department of Error.  378:30-30. 2011
• Aspirin in the prevention of cancer.  377:1649-1650. 2011
• Ageing faster with AIDS in Africa.  377:1131-1133. 2011
• Department of Error.  377:1408-1408. 2011
• Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial.  377:1409-1420. 2011
• Aerosol drug delivery: developments in device design and clinical use.  377:1032-1045. 2011
• New drug development.  377:901-902. 2011
• The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial.  377:1096-1101.e2. 2011
• Stemming the global tsunami of cardiovascular disease.  377:529-532. 2011
• Double-dose clopidogrel in patients undergoing PCI for ACS – Authors' reply.  377:298-298. 2011
• Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial.  376:1838-1845. 2010
• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials.  376:1670-1681. 2010
• How generalisable is INTERSTROKE? – Authors' reply.  376:1539-1539. 2010
• Antiphospholipid syndrome.  376:1498-1509. 2010
• Can we increase male involvement in AIDS treatment?.  376:1302-1302. 2010
• Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial.  376:1233-1243. 2010
• Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial.  376:975-983. 2010
• Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.  376:419-430. 2010
• Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial.  376:23-32. 2010
• Low-dose combination therapy with rosiglitazone and metformin to prevent type 2 diabetes mellitus (CANOE trial): a double-blind randomised controlled study.  376:103-111. 2010
• Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.  376:112-123. 2010
• More insights on the dysglycaemia–cardiovascular connection.  375:2195-2196. 2010
• Mendelian randomisation, triglycerides, and CHD.  375:1584-1586. 2010
• Is there an ethical obligation to complete polio eradication?.  375:1340-1341. 2010
• Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.  375:807-815. 2010
• InFACT: a global critical care research response to H1N1.  375:11-13. 2010
• Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.  374:2055-2063. 2009
• Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials.  374:2064-2071. 2009
• Anticoagulants for patients with prosthetic heart valves – Authors' reply.  374:1499-1500. 2009
• Methodologists are not qualified to write clinical guidelines – Authors' reply.  374:1327-1327. 2009
• Challenges in evaluating surgical innovation.  374:1097-1104. 2009
• Evaluation and stages of surgical innovations.  374:1089-1096. 2009
• No surgical innovation without evaluation: the IDEAL recommendations.  374:1105-1112. 2009
• Otamixaban in acute coronary syndromes.  374:762-764. 2009
• The Indian Polycap Study (TIPS) – Authors' reply.  374:782-782. 2009
• To cement or not in hip fracture surgery?.  374:1047-1049. 2009
• Albuminuria in chronic heart failure: prevalence and prognostic importance.  374:543-550. 2009
• Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends.  374:565-576. 2009
• From BODE to ADO to outcomes in multimorbid COPD patients.  374:667-668. 2009
• Phosphodiesterase-4 inhibition in COPD.  374:665-667. 2009
• Rivaroxaban versus enoxaparin after total knee arthroplasty.  374:681-681. 2009
• Rivaroxaban versus enoxaparin after total knee arthroplasty – Authors' reply.  374:683-683. 2009
• Lipid lowering for primary prevention (vol 373, pg 1152, 2009).  374:28-28. 2009
• Clinical experts or methodologists to write clinical guidelines?.  374:273-275. 2009
• Expanding HIV care in Africa: making men matter.  374:275-276. 2009
• Does ratification of human-rights treaties have effects on population health?.  373:1987-1992. 2009
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.  373:1673-1680. 2009
• Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.  373:1341-1351. 2009
• Interference, intimidation, and measuring mortality in war.  373:1320-1322. 2009
• Lipid lowering for primary prevention.  373:1152-1155. 2009
• Make the money work for health in sub-Saharan Africa.  373:1174-1174. 2009
• Responding to child maltreatment – Authors' reply.  373:1251-1251. 2009
• Antenatal corticosteroids to prevent preterm birth – Authors' reply.  373:894-894. 2009
• Lancet Steering Group on the occupied Palestinian territory.  373:788-790. 2009
• A vision statement on guideline development for respiratory disease: the example of COPD.  373:774-779. 2009
• Telmisartan in high-risk patients intolerant of ACE inhibitors – Authors' reply.  373:459-459. 2009
• Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.  373:137-146. 2009
• Interventions to prevent child maltreatment and associated impairment.  373:250-266. 2009
• Recognising and responding to child maltreatment.  373:167-180. 2009
• Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised controlled trial.  372:2143-2151. 2008
• Renal outcomes in the ONTARGET study – Authors' reply.  372:2020-2021. 2008
• Sustainability science: an integrated approach for health-programme planning.  372:1579-1589. 2008
• Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial (vol 372, pg 1174, 2008).  372:1384-1384. 2008
• Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.  372:1174-1183. 2008
• Exhaled nitric oxide in guideline-based asthma management.  372:1015-1017. 2008
• Supporting the delivery of cost-effective interventions in primary health-care systems in low-income and middle-income countries: an overview of systematic reviews.  372:928-939. 2008
• The coming of age of asthma guidelines.  372:1021-1022. 2008
• β-blocker therapy in non-cardiac surgery – Authors' reply.  372:1146-1146. 2008
• Guidelines for anticoagulant use in acute coronary syndromes – Authors' reply.  372:533-534. 2008
• Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.  372:547-553. 2008
• Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study.  372:224-233. 2008
• Selective factor Xa inhibition for thromboprophylaxis.  372:6-8. 2008
• Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.  371:1839-1847. 2008
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2).  371:1675-1684. 2008
• Guidelines for anticoagulant use in acute coronary syndromes.  371:1559-1561. 2008
• Cardiotoxicity associated with sunitinib.  371:1244-1244. 2008
• Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data.  371:1435-1442. 2008
• Endoscopic treatments for gastro-oesophageal reflux disease.  371:965-966. 2008
• Effects of policy options for human resources for health: an analysis of systematic reviews.  371:668-674. 2008
• Should active recruitment of health workers from sub-Saharan Africa be viewed as a crime?.  371:685-688. 2008
• An overview of mortality and sequelae of preterm birth from infancy to adulthood.  371:261-269. 2008
• Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis.  371:117-125. 2008
• A wake-up call for global access to salvage HIV drug regimens.  370:1885-1887. 2007
• Do human rights matter to health? (vol 370, pg 521, 2007).  370:1686-1686. 2007
• Patient-important outcomes in diabetes—time for consensus.  370:1104-1106. 2007
• Sequential regimens for Helicobacter pylori eradication.  370:1010-1012. 2007
• Use of evidence in WHO recommendations.  370:825-826. 2007
• Use of evidence in WHO recommendations – Authors' reply.  370:826-827. 2007
• Do human rights matter to health?.  370:521-527. 2007
• History, principles, and practice of health and human rights.  370:449-455. 2007
• Neglected diseases, civil conflicts, and the right to health.  370:619-627. 2007
• Not a broken heart.  370:628-628. 2007
• Use of evidence in WHO recommendations..  369:1883-1889. 2007
• Use of evidence in WHO recommendations.  369:1883-1889. 2007
• Thromboembolism prevention in ischaemic stroke.  369:1413-1415. 2007
• Prevention of vascular events in atrial fibrillation – Authors' reply.  369:106-106. 2007
• Strategies to avoid the loss of developmental potential in more than 200 million children in the developing world.  369:229-242. 2007
• The DREAM trial – Authors' reply.  368:2050-2051. 2006
• Asthma as a disease concept.  368:1415-1416. 2006
• Thioguanine versus mercaptopurine in childhood ALL.  368:1304-1306. 2006
• Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.  368:1096-1105. 2006
• Helicobacter pylori and gastro-oesophageal reflux disease – Authors' reply.  368:986-987. 2006
• Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials.  368:581-588. 2006
• ESPRIT trial.  368:447-447. 2006
• Pharmacological management of mild or moderate persistent asthma.  368:794-803. 2006
• Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study.  368:647-658. 2006
• Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis.  368:371-378. 2006
• The decline of academic medicine.  368:284-284. 2006
• Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.  367:1903-1912. 2006
• Gastro-oesophageal reflux disease.  367:2086-2100. 2006
• Deeper lessons from the CMAJ debacle.  367:1551-1553. 2006
• Free doctors and medical students detained in Nepal.  367:1730-1730. 2006
• Obesity and risk of myocardial infarction: the INTERHEART study – Author's reply.  367:1054-1054. 2006
• Syndromic approach for treatment of STIs: time for a change.  367:1380-1381. 2006
• Aspirin resistance.  367:606-617. 2006
• Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial.  366:2005-2011. 2005
• Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.  366:2087-2106. 2005
• Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study.  366:1640-1649. 2005
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins.  366:1267-1278. 2005
• Haemoglobin E β thalassaemia in Sri Lanka.  366:1467-1470. 2005
• Adjuvant trastuzumab for HER2-positive breast cancer.  366:634-634. 2005
• Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial.  366:463-471. 2005
• Deep vein thrombosis.  366:118-118. 2005
• Blinded by pressure and pain.  365:2244-2244. 2005
• Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study.  365:2098-2104. 2005
• Effectiveness of home visitation by public-health nurses in prevention of the recurrence of child physical abuse and neglect: a randomised controlled trial.  365:1786-1793. 2005
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.  365:1687-1717. 2005
• Selective head cooling after neonatal encephalopathy.  365:1619-1619. 2005
• Homocysteine and stroke.  365:194-196. 2005
• INTERHEART.  365:117-117. 2005
• INTERHEART.  365:118-118. 2005
• INTERHEART.  365:119-120. 2005
• Zero tolerance for domestic violence.  365:120-120. 2005
• Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study (vol 364, pg 937m 2004).  364:2020-2020. 2004
• Department of Error.  364:2020-2020. 2004
• Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study (vol 364, pg 937, 2004).  364:1938-1938. 2004
• Implications of the draft European Union services directive for health care.  364:1200-1202. 2004
• Use of research to inform public policymaking.  364:1615-1621. 2004
• Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study.  364:953-962. 2004
• B-Aware:recall of intra-operative events.  364:840-840. 2004
• B-Aware:recall of intra-operative events.  364:841-841. 2004
• Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.  364:937-952. 2004
• Informed choices for attaining the Millennium Development Goals: towards an international cooperative agenda for health-systems research.  364:997-1003. 2004
• Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial.  364:513-520. 2004
• The McMaster- Lancet health and peace conferences.  364:311-312. 2004
• Selective quotation of evidence in vaccines research.  363:1738-1738. 2004
• Improving patients' safety locally: changing clinician behaviour.  363:1224-1230. 2004
• Ximelagatran or warfarin in atrial fibrillation?.  363:734-734. 2004
• Innovation and placebos in research: a new design of clinical trial.  362:2036-2037. 2003
• Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery..  362:1581. 2003
• Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.  362:1527-1535. 2003
• Fondaparinux and prevention of venous thromboembolism after orthopaedic surgery.  362:1582-1583. 2003
• The CHARM programme.  362:1675-1676. 2003
• The CHARM programme.  362:1678-1679. 2003
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.  362:777-781. 2003
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.  362:772-776. 2003
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.  362:767-771. 2003
• Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme.  362:759-766. 2003
• The public health implications of world trade negotiations on the general agreement on trade in services and public services.  362:1072-1075. 2003
• Assessment of efficacy of varicocele repair for male subfertility: a systematic review.  361:1849-1852. 2003
• Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study.  361:1843-1848. 2003
• Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial.  361:1071-1076. 2003
• Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study.  361:1077-1083. 2003
• Heart Protection Study.  361:528-528. 2003
• Heart Protection Study.  361:530-530. 2003
• Mortality and indicators of traffic-related air pollution.  361:430-430. 2003
• Breastfeeding, atopy, and asthma..  361:174. 2003
• Erratum: Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: A systematic review (Lancet (October 5) (1037)).  361:90. 2003
• Breastfeeding, atopy, and asthma.  361:175-176. 2003
• Tobacco money: up in smoke?.  360:1981-1981. 2002
• Association between children's experience of socioeconomic disadvantage and adult health: a life-course study.  360:1640-1645. 2002
• Do editors live up to the Sept 10, 2001, expectations?.  360:1606-1606. 2002
• Do editors live up to the Sept 10, 2001, expectations?.  360:1605-1606. 2002
• Fondaparinux versus enoxaparin for prevention of venous thromboembolism.  360:1603-1604. 2002
• Fondaparinux versus enoxaparin for prevention of venous thromboembolism.  360:1605-1605. 2002
• Erratum: Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: A rondomised double-blind trial (Lancet (May 18) (1721)).  360:1102. 2002
• Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review.  360:1037-1043. 2002
• Long-term relation between breastfeeding and development of atopy and asthma in children and young adults: a longitudinal study.  360:901-907. 2002
• Prenatal exclusion of β thalassaemia major by examination of maternal plasma.  360:998-1000. 2002
• Who is fooling us?.  360:873-874. 2002
• Direct thrombin inhibitors in acute coronary syndromes.  360:491-492. 2002
• Direct thrombin inhibitors in acute coronary syndromes.  360:492-492. 2002
• How to spread information.  360:493-493. 2002
• Ibuprofen prophylaxis in preterm neonates.  360:492-492. 2002
• Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial.  360:47-53. 2002
• Two decades of progress in preventing vascular disease.  360:2-3. 2002
• What kind of evidence do we need to justify humanitarian medical aid?.  360:330-333. 2002
• Blood pressure and cardiovascular risk in the HOPE study.  359:2118-2118. 2002
• Blood pressure and cardiovascular risk in the HOPE study.  359:2117-2118. 2002
• Helicobacter pylori and peptic-ulcer disease.  359:1943-1943. 2002
• Helicobacter pylori and peptic-ulcer disease.  359:1944-1944. 2002
• The tip of the iceberg?.  359:2194-2194. 2002
• Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.  359:1721-1726. 2002
• Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.  359:1715-1720. 2002
• Market forces in public health.  359:1363-1364. 2002
• Clopidogrel and percutaneous coronary intervention.  359:169-169. 2002
• Clopidogrel and percutaneous coronary intervention.  359:169-169. 2002
• Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data.  359:294-302. 2002
• Effect of visual-spatial ability on learning of spatially-complex surgical skills.  359:230-231. 2002
• Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis.  359:14-22. 2002
• Blood-pressure reduction and cardiovascular risk in HOPE study.  358:2130-2131. 2001
• Cardiopulmonary resuscitation directives on admission to intensive-care unit: an international observational study.  358:1941-1945. 2001
• Not a drop to drink in the Aral Sea.  358:1649-1649. 2001
• Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP).  358:1147-1153. 2001
• Effect of world trade on public health.  358:1097-1097. 2001
• Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.  358:702-710. 2001
• Broad-spectrum antibiotics in ORACLE.  358:502-502. 2001
• Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study.  358:527-533. 2001
• Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials.  358:9-15. 2001
• Behavioural problems in children who weigh 1000 g or less at birth in four countries.  357:1641-1643. 2001
• Health and peace: time for a new discipline.  357:1460-1461. 2001
• Venous thromboembolism after long flights: are airlines to blame?.  357:1461-1462. 2001
• How medical students learn spatial anatomy.  357:363-364. 2001
• Vitamin K in anticoagulation therapy.  357:637-637. 2001
• Vitamin K in anticoagulation therapy.  357:638-638. 2001
• Term breech trial..  357:225. 2001
• Term breech trial.  357:227-228. 2001
• Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials.  356:1955-1964. 2000
• Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response.  356:2144-2148. 2000
• Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response.  356:2149-2153. 2000
• Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial.  356:2037-2044. 2000
• Rewriting the regulations: how the World Trade Organisation could accelerate privatisation in health-care systems.  356:1995-2000. 2000
• Intracranial haemorrhage with bolus thrombolytic agents.  356:1848-1848. 2000
• Intracranial haemorrhage with bolus thrombolytic agents.  356:1850-1850. 2000
• Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial.  356:1551-1553. 2000
• Planned caesarean section versus planned vaginal birth for breech presentation at term: a randomised multicentre trial.  356:1375-1383. 2000
• Management of unstable angina and myocardial infarction.  356:1193-1194. 2000
• Recognition of premenstrual dysphoric disorder and its treatment.  356:1126-1127. 2000
• Erratum: Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: A meta-analysis (Lancet (2000) 3 June (1936)).  356:600. 2000
• Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis (vol 355, pg 1936, 2000).  356:600-600. 2000
• Long-term safety and efficacy of omeprazole in gastro-oesophageal reflux disease.  356:610-612. 2000
• Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis.  356:449-454. 2000
• Treatment of severe systemic lupus erythematosus with high-dose chemotherapy and haemopoietic stem-cell transplantation: a phase I study.  356:701-707. 2000
• A commitment to curbing the pandemic of cardiovascular disease.  356:347-347. 2000
• Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE).  356:279-284. 2000
• Medical migration: who are the real losers?.  356:245-246. 2000
• Stability and sterility of recombinant tissue plasminogen activator at −30°C.  355:2221-2221. 2000
• Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis.  355:1936-1942. 2000
• Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial.  355:1665-1669. 2000
• Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients.  355:1575-1581. 2000
• Short-acting inhaled β-agonists: to be taken regularly or as needed?.  355:1658-1659. 2000
• Worrisome striae.  355:1692-1692. 2000
• Fetal growth restriction.  355:1366-1367. 2000
• Nosocomial influenza infection.  355:1187-1188. 2000
• Pertussis transmission in England and Wales.  355:1553-1553. 2000
• Pertussis transmission in England and Wales.  355:1553-1554. 2000
• The HOPE study and diabetes.  355:1181-1181. 2000
• The HOPE study and diabetes.  355:1183-1184. 2000
• Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview.  355:773-778. 2000
• Management of unstable coronary-artery disease.  355:572-572. 2000
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.  355:253-259. 2000
• Impact of immunisation on pertussis transmission in England and Wales.  355:285-286. 2000
• Risk of congenital malformations associated with treatment of asthma during early pregnancy.  355:119-119. 2000
• Albert Einstein's brain..  354:1821-1822. 1999
• Albert Einstein's brain.  354:1822-1822. 1999
• How the World Trade Organisation is shaping domestic policies in health care.  354:1889-1892. 1999
• Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement.  354:1896-1900. 1999
• Symptoms of reproductive-tract infection—not all that they seem to be.  354:1745-1746. 1999
• 18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease.  354:836-837. 1999
• Lifeline - Salim Yusuf.  354:876-876. 1999
• 18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease.  354:836-837. 1999
• Diagnosis of left-ventricular dysfunction from induced sputum examination.  354:833-834. 1999
• Erratum: The exceptional brain of Albert Einstein (The Lancet (1999) June 19 (2149)).  354:258. 1999
• Homocysteine and vascular disease.  354:407-413. 1999
• Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial.  353:2179-2184. 1999
• The exceptional brain of Albert Einstein.  353:2149-2153. 1999
• Erratum: New antithrombotic agents (The Lancet (1999) April 24 (1431)).  353:1804. 1999
• New antithrombotic agents (vol 353, pg 1431, 1999).  353:1804-1804. 1999
• Asthma exacerbations.  353:1443-1443. 1999
• New antithrombotic agents.  353:1431-1436. 1999
• Prognosis in acute pulmonary embolism.  353:1375-1376. 1999
• Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial.  353:429-438. 1999
• Preventive medicine in a diabetes clinic: an opportunity to make a difference.  353:606-608. 1999
• Leukotrienes and the brain.  352:1487-1488. 1998
• Variations between countries in invasive cardiac procedures.  352:1469-1469. 1998
• Variations between countries in invasive cardiac procedures.  352:1470-1471. 1998
• Polychemotherapy for early breast cancer: an overview of the randomised trials.  352:930-942. 1998
• Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?.  352:609-613. 1998
• Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation.  352:507-514. 1998
• Reappraisal of Malthus.  352:241-242. 1998
• Meta-analysis.  351:1960-1960. 1998
• Tamoxifen for early breast cancer: an overview of the randomised trials.  351:1451-1467. 1998
• Male erectile dysfunction.  351:757-758. 1998
• Overcoming the limitations of current meta-analysis of randomised controlled trials.  351:47-52. 1998
• Randomised trial to assess safety and fetal outcome of early and midtrimester amniocentesis.  351:242-247. 1998
• Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data.  350:1647-1654. 1997
• Angiotensin-converting-enzyme inhibitors in early pregnancy.  350:1446-1447. 1997
• Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials.  350:1417-1424. 1997
• Descriptive epidemiology of asthma.  350:S1-S4. 1997
• Epidemiology of childhood asthma.  350:1015-1020. 1997
• Living a little more dangerously.  350:1164-1165. 1997
• To treat or not to treat?.  350:820-821. 1997
• Treatment of thalassaemia major with phenylbutyrate and hydroxyurea.  350:491-492. 1997
• Intracoronary-stent placement for coronary artery disease..  350:113-114. 1997
• Amiodarone after myocardial infarction: EMIAT and CAMIAT trials..  349:1767. 1997
• Blood pressure in pregnancy and fetal growth..  349:802. 1997
• Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT.  349:675-682. 1997
• Treatment of mild asthma.  349:818-818. 1997
• CAPRIE trial.  349:356-356. 1997
• CAPRIE trial..  349:354-355. 1997
• Ambulatory blood pressure in pregnancy and fetal growth.  349:7-10. 1997
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).  348:1329-1339. 1996
• Ovarian ablation in early breast cancer: overview of the randomised trials.  348:1189-1196. 1996
• Risk factors for coronary heart disease in Asian Indians.  348:1242-1242. 1996
• Increased fetal loss in women with heritable thrombophilia.  348:913-916. 1996
• Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease.  348:1115-1119. 1996
• Post-discharge deep-vein thrombosis after orthopaedic surgery.  348:1180-1180. 1996
• Risk factors for acute myocardial infarction in Indians: a case-control study.  348:358-363. 1996
• Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications.  348:383-386. 1996
• Medicine and the media.  348:62-62. 1996
• Dysglycaemia and risk of cardiovascular disease - Reply.  347:1834-1835. 1996
• Dysglycaemia and risk of cardiovascular disease.  347:1833-1835. 1996
• Dysglycaemia and risk of cardiovascular disease.  347:949-950. 1996
• Hirudin and thrombosis prophylaxis.  347:632-633. 1996
• Red-cell antibodies in pregnancy: evidence overturned.  347:485-486. 1996
• Psychometric scores and persistence of irritable bowel after infectious diarrhoea.  347:150-153. 1996
• Evidence-based medicine.  346:1300-1300. 1995
• Evidence-based medicine.  346:1171-1172. 1995
• Evidence-based medicine..  346:839. 1995
• Preventive health care.  345:1611-1615. 1995
• Accuracy of clinical assessment of deep-vein thrombosis.  345:1326-1330. 1995
• Report card from McMaster: student evaluation at a problem-based medical school.  345:899-902. 1995
• Asthma deaths in New Zealand.  345:655-656. 1995
• ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction.  345:669-685. 1995
• Diagnosis of Chlamydia trachomatis genitourinary infection in women by ligase chain reaction assay of urine.  345:213-216. 1995
• Dermatan sulphate in heparin-induced thrombocytopenia.  344:1295-1296. 1994
• Randomised controlled trial of respiratory rehabilitation.  344:1394-1397. 1994
• EFFECT OF CORONARY-ARTERY BYPASS GRAFT-SURGERY ON SURVIVAL - REPLY.  344:1224-1224. 1994
• SALIVARY ANTIBODIES TO HELICOBACTER-PYLORI - SCREENING DYSPEPTIC PATIENTS BEFORE ENDOSCOPY.  344:1016-1017. 1994
• Does immunological intercourse prevent pre-eclampsia?.  344:969-970. 1994
• Effect of coronary artery bypass graft surgery on survival.  344:1222-1224. 1994
• Is chest pain after sumatriptan oesophageal in origin?.  344:985-986. 1994
• Salivary antibodies to Helicobacter pylori: screening dyspeptic patients before endoscopy.  344:1016-1017. 1994
• Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration.  344:563-570. 1994
• Regular versus as-needed inhaled salbutamol in asthma control.  344:621-621. 1994
• Asthma control.  344:344-344. 1994
• Stress without distress: the intrauterine perspective.  344:73-74. 1994
• GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico..  343:1115-1122. 1994
• Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer.  343:886-889. 1994
• Microfilaria, tolerance, and T cells.  343:868-869. 1994
• Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients.  343:311-322. 1994
• Immunocytological test to detect adult carriers of (--SEA/) deletional α-thalassaemia.  342:1145-1147. 1993
• Primidone and rapid cycling affective disorders.  342:925-925. 1993
• RESPIRATORY DISEASE.  341:1377-1378. 1993
• ACE inhibitors for myocardial infarction and unstable angina.  341:829-829. 1993
• How much ethics is needed to make a good doctor?.  341:498-499. 1993
• Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.  340:1173-1178. 1992
• How safe is BCG vaccination in children born to HIV-positive mothers?.  340:434-435. 1992
• Transmission of hepatitis C with pasteurised factor VIII.  340:305-306. 1992
• Aortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand's disease the link?.  340:35-37. 1992
• Central-nervous-system dysfunction after warm or hypothermic cardiopulmonary bypass.  339:1383-1384. 1992
• ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction.  339:753-770. 1992
• Voluntary dehydration and heat intolerance in cystic fibrosis.  339:696-699. 1992
• Second chance for the adrenal medulla transplant.  339:431-431. 1992
• Recombinant factor VIII concentrate.  339:61-62. 1992
• Dose reduction of beta-agonists in asthma.  338:1331-1332. 1991
• Iron in neuroleptic malignant syndrome.  338:820-821. 1991
• Serum iron and neuroleptic malignant syndrome.  338:149-151. 1991
• Cyclophosphamide and plasma exchange in multiple sclerosis.  337:1540-1541. 1991
• Effects of occupational therapy home service on patients with rheumatoid arthritis.  337:1453-1456. 1991
• β2-agonists.  337:426-427. 1991
• Ferioterol and fatal asthma.  337:186-187. 1991
• Inhibition of Helicobacter pylori by acetohydroxamic acid.  336:1584-1585. 1990
• Regular inhaled beta-agonist treatment in bronchial asthma.  336:1391-1396. 1990
• MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction.  336:65-71. 1990
• Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.  335:1051-1055. 1990
• Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up.  335:270-273. 1990
• Fenoterol and fatal asthma.  335:45-46. 1990
• COMPARISON OF DAILY AND TWICE-WEEKLY REGIMENS TO TREAT PULMONARY TUBERCULOSIS.  334:1173-1176. 1989
• FENOTEROL AND FATAL ASTHMA.  334:45-45. 1989
• CHRONIC COUGH: EOSINOPHILIC BRONCHITIS WITHOUT ASTHMA.  333:1346-1348. 1989
• THE CANADIAN AMERICAN TICLOPIDINE STUDY (CATS) IN THROMBOEMBOLIC STROKE.  333:1215-1220. 1989
• FENOTEROL AND FATAL ASTHMA.  333:1070-1071. 1989
• SUCCESSFUL USE OF RECOMBINANT FACTOR VIIa IN PATIENT WITH SEVERE HAEMOPHILIA A DURING SYNOVECTOMY.  332:1193-1193. 1988
• DEVELOPMENT OF ANTI-IDIOTYPIC ANTIBODIES AGAINST TUMOUR ANTIGENS AND AUTOANTIGENS IN OVARIAN CANCER PATIENTS TREATED INTRAPERITONEALLY WITH MOUSE MONOCLONAL ANTIBODIES.  332:894-897. 1988
• HOSPITAL ADMINISTRATOR'S PARADOX.  332:1026-1026. 1988
• GALLSTONE LITHOTRIPSY.  332:457-458. 1988
• H2-RECEPTOR ANTAGONIST NON-RESPONDERS.  332:275-275. 1988
• RANDOMISED COMPARISON OF TWO INTENSITIES OF ORAL ANTICOAGULANT THERAPY AFTER TISSUE HEART VALVE REPLACEMENT.  331:1242-1245. 1988
• EFFECT OF INTRAVENOUS NITRATES ON MORTALITY IN ACUTE MYOCARDIAL-INFARCTION - AN OVERVIEW OF THE RANDOMIZED TRIALS.  1:1088-1092. 1988
• SCREENING FOR INHERITED METABOLIC DISEASES IN ADULTS WITH NEUROLOGICAL DISEASE.  1:1101-1101. 1988
• EFFECT OF INTRAVENOUS NITRATES ON MORTALITY IN ACUTE MYOCARDIAL INFARCTION: AN OVERVIEW OF THE RANDOMISED TRIALS.  331:1088-1092. 1988
• USE OF OXYGEN THERAPY FOR ADULT PATIENTS OUTSIDE THE CRITICAL CARE AREAS OF A UNIVERSITY HOSPITAL.  331:981-983. 1988
• CADMIUM FUME INHALATION AND EMPHYSEMA.  331:663-667. 1988
• CHARGES FOR PREVENTIVE SERVICES.  331:245-245. 1988
• HLA-DQ BETA-CHAIN POLYMORPHISM IN HLA-DR4 HAPLOTYPES ASSOCIATED WITH RHEUMATOID ARTHRITIS.  330:1118-1120. 1987
• HEPATITIS B VACCINE AND HEALTH WORKERS' COMPENSATION CLAIMS.  330:913-914. 1987
• POSSIBLE MECHANISM FOR CEREBRAL OEDEMA IN DIABETIC KETOACIDOSIS.  330:306-308. 1987
• DNA DIAGNOSTIC LABORATORIES.  329:1434-1434. 1987
• FALSE NEGATIVE RESULT BY THE WELLCOZYME ANTI-HIV ASSAY IN TESTING AN HIV POSITIVE HAEMOPHILIAC.  329:1200-1201. 1987
• PROSTAGLANDINS FOR PEPTIC ULCER DISEASE.  329:1262-1262. 1987
• CHORIONIC VILLUS SAMPLING FOLLOWED BY GENETIC AMNIOCENTESIS AND SEPTIC SHOCK.  329:867-868. 1987
• OESTROGEN MODULATORS AND CLEAR CELL CARCINOMA OF VAGINA.  329:913-913. 1987
• DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE.  329:523-526. 1987
• SIMULATED CARDIAC ARRESTS FOR MONITORING QUALITY OF IN-HOSPITAL RESUSCITATION.  328:618-620. 1986
• UNEXPECTED MOBILISATION OF LEAD DURING CISPLATIN CHEMOTHERAPY.  328:249-250. 1986
• SINGLE-PATIENT RANDOMISED CLINICAL TRIAL Use in Determining Optimum Treatment for Patient with Inflammation of Kock Continent Ileostomy Reservoir.  327:726-728. 1986
• CONDUCTION BLOCK IN EARLY GUILLAIN-BARRE SYNDROME.  327:332-332. 1986
• TAMOXIFEN PROPHYLAXIS.  327:263-265. 1986
• PSYCHOTIC SYMPTOMS IN VOLUNTEERS SERVING OVERSEAS.  326:37-37. 1985
• CHORIONIC VILLUS SAMPLING.  325:1269-1270. 1985
• NOCTURNAL DOSES OF H2 RECEPTOR ANTAGONISTS FOR DUODENAL ULCER.  325:647-648. 1985
• ACUTE VINCRISTINE NEUROTOXICITY.  325:346-346. 1985
• ANGIOIMMUNOBLASTIC LYMPHADENOPATHY ASSOCIATED WITH RESERPINE.  324:820-821. 1984
• WRIGHT'S b DETERMINANT, MONOCLONAL ANTIBODIES, AND PLASMODIUM FALCIPARUM MEROZOITE INVASION.  324:934-935. 1984
• RANITIDINE 150 mg TWICE DAILY VS 300 mg NIGHTLY IN TREATMENT OF DUODENAL ULCERS.  324:274-276. 1984
• POST-PARTUM HAEMOLYTIC URAEMIC SYNDROME AND VEROTOXIN-PRODUCING ESCHERICHIA COLI.  323:511-511. 1984
• CYTOGENETICS IN THE EVALUATION OF PERINATAL DEATH.  1:630-631. 1984
• INGESTION OF EGG RAISES PLASMA LOW-DENSITY LIPOPROTEINS IN FREE-LIVING SUBJECTS.  1:647-649. 1984
• H2-BLOCKERS: NIGHT-TIME ONLY.  322:1371-1371. 1983
• ENHANCEMENT OF HUMAN IMPLANTATION BY EXOGENOUS CHORIONIC GONADOTROPIN.  322:1191-1191. 1983
• RENAL DYSFUNCTION IN CADMIUM SMELTERS: RELATION TO IN-VIVO LIVER AND KIDNEY CADMIUM CONCENTRATIONS.  321:1185-1187. 1983
• BLEEDING AND DIVERTICULAR DISEASE.  321:830-830. 1983
• PEPPERMINT OIL TO REDUCE COLONIC SPASM DURING ENDOSCOPY.  320:989-989. 1982
• BRAIN TYPE CPK-BB AND CEREBRAL ISCHAEMIA AFTER SUBARACHNOID HAEMORRHAGE.  320:662-663. 1982
• ANGIODYSPLASIA OF THE COLON.  320:16-19. 1982
• INTRAGASTRIC ACIDITY, BACTERIA, NITRITE, AND N-NITROSO COMPOUNDS BEFORE, DURING, AND AFTER CIMETIDINE TREATMENT.  319:1091-1095. 1982
• ANGIODYSPLASIA.  318:1340-1340. 1981
• EVALUATING NEONATAL INTENSIVE CARE.  318:1052-1052. 1981
• ETOPOSIDE: A NEW ANTI-CANCER AGENT.  318:912-915. 1981
• ATENOLOL, HEPARIN AND THE INTERMEDIATE CORONARY SYNDROME.  318:46-46. 1981
• ACETAZOLAMIDE IN THE MOUNTAINS.  317:552-553. 1981
• DETECTION OF LEUCOCYTES IN PERITONEAL EFFLUENT BY TEST STRIP.  317:437-438. 1981
• EVALUATING NEONATAL INTENSIVE-CARE.  2:1052-1052. 1981
• CEREBRAL ŒDEMA IN FATAL MENINGOCOCCÆMIA.  316:967-969. 1980
• Cerebral oedema in fatal meningococcaemia..  2:967-969. 1980
• MATERNAL HYPERPROLINÆMIA.  316:981-982. 1980
• ŒSTROGEN USE AND SURVIVAL IN ENDOMETRIAL CANCER.  316:961-964. 1980
• EARLY INTRAVENOUS ATENOLOL TREATMENT IN SUSPECTED ACUTE MYOCARDIAL INFARCTION.  316:273-276. 1980
• SMALL-CELL LUNG CANCER.  315:252-252. 1980
• CAPTOPRIL-ASSOCIATED AGRANULOCYTOSIS.  315:150-150. 1980
• MATERNAL HYPERPROLINEMIA.  2:982-983. 1980
• WORK-SITE TREATMENT OF HYPERTENSION BY SPECIALLY TRAINED NURSES.  314:1175-1178. 1979
• EFFECT OF ATENOLOL ON RECOVERY OF THE ELECTROCARDIOGRAPHIC SIGNS OF MYOCARDIAL INFARCTION.  314:868-869. 1979
• ISCHqMIC HEART-DISEASE AND GARLIC.  314:104-105. 1979
• CADMIUM IN SHIPHAM.  313:551-551. 1979
• MISDIAGNOSES OF ENDOGENOUS DEPRESSION WITH RESEARCH DIAGNOSTIC CRITERIA.  313:267-267. 1979
• CRITICAL CONCENTRATION OF CADMIUM IN RENAL CORTEX AND URINE.  313:221-221. 1979
• INSOMNIA, SEDATION, AND HIGH ALTITUDE CEREBRAL $OElig;DEMA.  313:165-165. 1979
• MIS-DIAGNOSES OF ENDOGENOUS-DEPRESSION WITH RESEARCH DIAGNOSTIC CRITERIA.  1:267-267. 1979
• USE OF CHRONIC CEREBELLAR STIMULATION FOR DISORDERS OF DISINHIBITION.  311:595-600. 1978
• PLATELET AGGREGATION INDUCED BY SWINE INFLUENZA VACCINE.  311:277-278. 1978
• ARTIFICIAL SWEETENERS AND HUMAN BLADDER CANCER.  310:578-581. 1977
• ESKIMOS AND MULTIPLE SCLEROSIS.  309:1370-1370. 1977
• MULTIPLE SCLEROSIS AND DOGS.  309:487-488. 1977
• INFECTION ACQUIRED IN THE PATHOLOGY LABORATORY.  308:1406-1407. 1976
• RICKETTSIA-LIKE BODIES AND SPLENITIS IN KAWASAKI DISEASE.  308:1254-1255. 1976
• IMPROVEMENT OF MEDICATION COMPLIANCE IN UNCONTROLLED HYPERTENSION.  307:1265-1268. 1976
• MINERAL-OIL CANCERS.  307:1082-1082. 1976
• TERMINAL TRANSFERASE IN HUMAN BONE-MARROW LYMPHOCYTES.  307:508-509. 1976
• HEALING OF GASTRIC ULCER DURING TREATMENT WITH CIMETIDINE.  307:337-339. 1976
• T AND B LYMPHOCYTES IN BREAST CANCER STAGE RELATIONSHIP AND ABROGATION OF T-LYMPHOCYTE DEPRESSION BY ENZYME TREATMENT IN VITRO.  307:330-333. 1976
• RANDOMISED CLINICAL TRIAL OF STRATEGIES FOR IMPROVING MEDICATION COMPLIANCE IN PRIMARY HYPERTENSION.  305:1205-1207. 1975
• RANDOMIZED CLINICAL TRIAL OF STRATEGIES FOR IMPROVING MEDICATION COMPLIANCE IN PRIMARY HYPERTENSION.  1:1205-1207. 1975
• TK-POLYAGGLUTINATION IN BACTEROIDES FRAGILIS SEPTICEMIA.  1:286-286. 1975
• EPIDEMIC OF AORTIC ANEURYSM?.  304:1575-1575. 1974
• MYOPATHIES: THE NEUROGENIC HYPOTHESIS.  304:42-42. 1974
• MOTONEURONE DISEASE AND AGEING.  302:1477-1480. 1973
• RELEVANCE OF PREOPERATIVE AND POSTOPERATIVE BLOOD TESTS TO POSTOPERATIVE LEG-VEIN THROMBOSIS.  302:805-809. 1973
• MEASUREMENT OF WHOLE-BODY NITROGEN BY NEUTRON-ACTIVATION ANALYSIS.  302:395-399. 1973
• THE DOUBLE CRUSH IN NERVE-ENTRAPMENT SYNDROMES.  302:359-362. 1973
• AUSTRALIAN MULTICENTRE TRIAL OF STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION.  301:57-60. 1973
• MEASUREMENT OF WHOLE-BODY NITROGEN BY NEUTRON-ACTIVATION ANALYSIS.  2:395-399. 1973
• FETAL/MATERNAL INCOMPATIBILITY.  300:1095-1096. 1972
• DEXAMETHASONE TREATMENT IN HERPES-SIMPLEX ENCEPHALITIS.  297:861-861. 1971
• " SICK " MOTONEURONES.  297:321-325. 1971
• DEXAMETHASONE TREATMENT IN HERPES-SIMPLEX ENCEPHALITIS.  297:290-291. 1971
• ALPHA RHYTHM: AN ARTEFACT?.  295:1109-1110. 1970
• MUSCULAR DYSTROPHY: MYOPATHY OR NEUROPATHY?.  295:1119-1119. 1970
• ELECTROENCEPHALOGRAPHY IN DIAGNOSIS OF HERPES-SIMPLEX ENCEPHALITIS.  295:650-652. 1970
• THE RESPONSIBILITIES OF THE CONSULTANT GRADE.  294:689-689. 1969
• METHOHEXITONE AND THE E.E.G..  294:110-110. 1969
• CLINICAL HÆMATOLOGY.  293:941-942. 1969
• CHANGES IN PLATELET BEHAVIOUR DURING ARVIN THERAPY.  293:644-647. 1969
• HÆMODIALYSIS IN THE HOME.  293:614-617. 1969
• HÆMOLYTIC-URÆMIC SYNDROME.  292:1394-1394. 1968
• CEPHALORIDINE TOXICITY.  291:47-48. 1968
• MICROANGIOPATHIC HÆMOLYTIC ANÆMIA.  291:90-90. 1968
• EXPERIMENTAL PRODUCTION OF MICROANGIOPATHIC HÆMOLYTIC ANÆMIA IN VIVO.  290:1121-1123. 1967
• RED-BLOOD-CELL FRAGMENTATION IN MICROANGIOPATHIC HÆMOLYTIC ANÆMIA: IN-VITRO STUDIES.  290:1123-1125. 1967
• RESOLUTION OF ACUTE MASSIVE PULMONARY EMBOLISM AFTER PULMONARY ARTERIAL INFUSION OF STREPTOKINASE.  290:593-597. 1967
• INTRAVASCULAR HÆMOLYSIS AND DISSEMINATED INTRAVASCULAR COAGULATION.  289:601-602. 1967
• CRI-DU-CHAT SYNDROME WITH AN APPARENTLY NORMAL KARYOTYPE.  2:326-+. 1967
• THE EMPHYSEMATOUS AND BRONCHIAL TYPES OF CHRONIC AIRWAYS OBSTRUCTION.  287:830-835. 1966
• PARENTAL AGE + SOURCE OF X CHROMOSOMES IN XXY KLINEFELTERS SYNDROME.  1:46-&. 1964
• CHROMOSOME ANALYSIS AND PARENTAL AGE IN DEL CASTILLO SYNDROME.  2:1121-&. 1963
• PORPHYRIA.  278:213-214. 1961
• HÆMOGLOBIN-H TRAIT IN A NEPALESE GURKHA WOMAN.  271:192-194. 1958
• We need to protect ourselves in our own way: Métis data principles for Métis data governance

has subject area

• 11 Medical and Health Sciences (FoR)
• General & Internal Medicine (Science Metrix)

Identity

International Standard Serial Number (ISSN)

• 0140-6736
• 1474-547X
• 2468-1253

Electronic International Standard Serial Number (EISSN)

• 1474-547X
• 2468-1253